Oncimmune Holdings full year results and conference call

DirectorsTalk Interviews

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, states that it will be announcing its full year results for the year ended 31st May 2020 on Friday, 30 October 2020.

Adam Hill, Chief Executive Officer, together with Matthew Hall, Chief Financial Officer, will host a presentation and conference call for analysts at 11:30am GMT on the day of the results.

For conference call details please contact Alexander Davis of FTI Consulting at [email protected] or 020 3727 1000.

The management team will also host on Investor Meet Company a live presentation of the results on Friday, 30 October at 15:00 GMT.

• The online presentation will be open to all existing shareholders and potential new investors.

• Questions can be submitted before the event via your Investor Meet Company dashboard or at any time during the live presentation via the “Ask a Question” function. Responses to the Q&A will be published at the earliest opportunity on the Investor Meet Company platform.

• Investor feedback can also be submitted directly to management immediately following the event.

Access to Investor Meet Company is free and interested parties can register to attend the presentation via the following link: https://www.investormeetcompany.com/essensys-plc/register-investor

Attendees who have already registered on the Investor Meet Company platform to meet the Oncimmune Holdings will automatically receive an invitation to the presentation.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Avation reports H1 FY2026 results with higher operating profit and reduced net debt

Avation PLC reported unaudited results for the six months ended 31 December 2025, with revenue of US$56.0 million and operating profit rising to US$29.3 million. Net indebtedness fell by US$61.5 million to US$542.7 million, while net asset value per share increased to £2.74.

WPP launches ‘Elevate28’ plan to simplify structure and restore growth

WPP has unveiled ‘Elevate28’, a multi-year strategy to transition to a single integrated company built around four operating units and its AI-driven WPP Open platform.

Derwent London agrees £110.5m sale of 90 Whitfield Street to Lone Star

Derwent London has exchanged contracts to sell 90 Whitfield Street, W1, to Lone Star Real Estate for £110.5m, reflecting a 5.0% net initial yield and a capital value of around £1,100 per sq ft. Completion is scheduled for August 2026, with proceeds to be reinvested into higher-returning projects and capital expenditure.

Howden Joinery Group reports 4.1% revenue growth and £345m PBT for 2025

Howdens delivered revenue of £2.4bn in 2025, up 4.1%, with profit before tax rising 5.1% to £344.9m. Gross margins improved to 62.7%, supported by efficiency savings and market share gains in the UK and international growth of 13.5%.

Hikma Pharmaceuticals delivers 2025 revenue growth in line with guidance

Hikma achieved 6% core revenue growth and maintained resilient margins in 2025, supported by strong Branded and Hikma Rx performance. The company outlined a cautious 2026 outlook, leadership changes, a 5% dividend increase, and a $250 million share buyback programme.

Rolls-Royce lifts mid-term targets after strong 2025 performance

Rolls-Royce Holdings plc delivered £3.5bn in underlying operating profit and £3.3bn in free cash flow for 2025, upgraded its 2028 guidance, and announced a £7bn–£9bn share buyback through 2028.

    Search

    Search